US Patent

US10702529 — Compositions and methods for treating insomnia

Formulation · Assigned to Eisai R&D Management Co Ltd · Expires 2035-10-21 · 9y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects compositions and methods for treating insomnia using a specific compound as an orexin receptor antagonist.

USPTO Abstract

In the present invention, compound such as (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl) cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.

Drugs covered by this patent

Patent Metadata

Patent number
US10702529
Jurisdiction
US
Classification
Formulation
Expires
2035-10-21
Drug substance claim
No
Drug product claim
Yes
Assignee
Eisai R&D Management Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.